Strategic Alliance Enhancing Drug Development
Radyus Research and Eurofins CDMO Alphora have forged a strategic partnership aiming to accelerate early-stage drug development for biotech firms around the globe. With Radyus based in the U.S. and Eurofins CDMO Alphora in Canada, the collaboration seeks to harness their strengths in operational research and development.
A Commitment to Excellence
This partnership is rooted in a mutual dedication to research and development excellence, focusing on long-term client collaborations rather than short-term transactions. By combining their expertise in preclinical development through to clinical proof-of-concept, Radyus and Alphora strive to minimize inefficiencies. The aim is to create a holistic service offering that enhances the prospects of drug program success.
Streamlining Processes for Better Outcomes
Radyus Research brings a wealth of experience in drug development strategy, including efficacy and safety testing, regulatory planning, and clinical trial management. Eurofins CDMO Alphora acts as the manufacturing powerhouse of the partnership, boasting a robust track record in process development and GMP manufacturing. This combined strength equips them to deliver effective and comprehensive solutions tailored for biopharmaceutical innovators.
Inspirational Leadership
According to Marta New, CEO of Radyus Research, "We're excited to launch this partnership and unlock the value for our clients. Our joint belief is that long-term collaboration is key to efficient drug development." The partnership will provide clients with world-class operating teams dedicated to achieving outstanding results.
Building Trust in Biopharma
Eurofins CDMO Alphora expressed enthusiasm about the alliance, highlighting that, "This partnership enhances our ability to deliver cohesive strategies and operational excellence across the development continuum." As they build a high-trust model, both organizations emphasize the importance of collaboration in the dynamically evolving biopharmaceutical landscape.
A Redefined Approach to Early-Stage Development
Through their partnership, Radyus Research and Eurofins CDMO Alphora are redefining early-stage drug development. They offer a unified services solution that is integrated, international, and dedicated to the sustained success of their clients.
About Radyus Research
Radyus Research specializes in integrated drug development, focusing on preclinical and early clinical program strategy, R&D operations, regulatory submissions, and program management. They support biotech companies from the optimization phase through to the clinical validation of innovative therapeutics and vaccines.
About Eurofins CDMO Alphora
Eurofins CDMO Alphora provides comprehensive process development and GMP manufacturing solutions for small molecular APIs, drug products, and biologics. They assist biopharmaceutical innovators from early development to commercialization, enhanced by the support of the global Eurofins network, which offers access to advanced analytical services and clinical logistics.
Frequently Asked Questions
What is the focus of the Radyus and Eurofins collaboration?
The partnership focuses on accelerating early-stage drug development for biotech companies globally.
How will this partnership benefit clients?
Clients will experience reduced inefficiencies and improved drug program success rates through a combined services offering.
What areas of expertise does Radyus bring?
Radyus contributes expertise in drug development strategy, animal testing, regulatory planning, and clinical trials.
What manufacturing capabilities does Eurofins provide?
Eurofins offers robust process development and GMP manufacturing for small molecule APIs and biologics.
Why is long-term collaboration emphasized?
Long-term collaboration is seen as crucial for fostering trust and ensuring efficient drug development outcomes.
